Skip to content

Immunological and Cardiovascular Phenotyping of Oocyte-donation Pregnancies

Immunological and Cardiovascular Phenotyping of Oocyte-donation Pregnancies

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04731012
Enrollment
1000
Registered
2021-01-29
Start date
2020-01-01
Completion date
2025-12-01
Last updated
2021-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oocyte-donation Pregnancies, Preeclampsia

Brief summary

The investigators conduct a study to evaluate the underlying causes of preeclampsia in oocyte-donation pregnancies.

Detailed description

A detailed medical history, questionnaires as well as blood, urine and placental samples will be used to analyse several factors leading to the high risk of preeclampsia in oocyte-donation pregnancies.

Interventions

None listed

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* pregnancy

Exclusion criteria

* severe auto immune disorders

Design outcomes

Primary

MeasureTime frameDescription
Preeclampsia in oocyte-donation pregnancies is caused by an altered composition of immune cells in placenta and blood.01.01.2020 - 01.12.2025T-Cell populations are altered in preeclampsia. HLA-mismatch of mother and donor oocyte lead to a host-versus-graft reaction. T-, B- and Natural killer cells are altered in placental tissue of oocyte-donation pregnancies.

Secondary

MeasureTime frameDescription
Preeclampsia in oocyte-donation pregnancies is caused by an activation of pro-inflammatory factors and endothelial dysfunction.01.01.2020 - 01.12.2025Altered Natural killer cells and B-cells in oocyte-donation pregnancies lead to endothelial dysfunction. Pro-inflammatory factors are higher in OD pregnancy and can be measured in placental tissue via single-cell sequencing.

Countries

Germany

Contacts

Primary ContactFlorian Herse, DSc
florian.herse@charite.de+49 30 450 540 434
Backup ContactJudith Altmann, MD
judith.altmann@charite.de

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026